Edit Optimization

In vivo therapeutic engineering is often framed as the next logical evolution of ex vivo cell and gene therapy. By eliminating complex manufacturing steps and enabling direct delivery of therapeutic payloads into the body, these approaches promise broader access, faster treatment timelines, and potentially lower cost.

For decades, cytogenetics has played a critical role in therapy development. It has helped us see when genomes are altered, unstable, or outright broken. But as cell and gene therapies become more sophisticated - and the margin for error shrinks - seeing is no longer enough.

Hematopoietic stem cells (HSCs) sit at the foundation of many cell and gene therapy programs. Whether used in autologous or allogeneic settings, ex vivo gene editing or viral transduction, HSCs are often treated as a standardized input—assumed to be equivalent as long as basic identity, viability, and purity criteria are met.